Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

The leader of an iconic apparel company and the co-founder and chair of Moderna are the honored speakers for the Worcester ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

In an early clinical trial, an experimental norovirus vaccine given as a pill produced defensive responses exactly where it counts—in the saliva of older people most vulnerable to the explosive ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

HEALTH chiefs have warned winter “is certainly not over” with norovirus hospitalisations still close to record highs – and ...

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

As announced on January 30, 2025, Elis delivered record full-year 2024 revenue of 4,573.7 million euros, up +6.1% ...

It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...